Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
How machine intelligence changes the rules of business by Marco Iansiti and Karim R. Lakhani In 2019, just five years after the Ant Financial Services Group was launched, the number of consumers using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results